The company proposes to utilise net proceeds from the fresh issue towards repayment of all or a portion of debt and general corporate purposes
Emcure Pharmaceuticals has filed its Draft Red Hearing Prospectus (DRHP) with market regulator Securities and Exchange Board of India (SEBI). The company plans to raise funds through the initial public offering comprising a fresh issue of equity shares aggregating up to Rs 1,100 crores (The Fresh Issue) and an offer for sale aggregating up to 18,168,356 equity shares (Offer for Sale). It includes Satish Mehta aggregating up to 2,030,000 equity shares and Sunil Mehta aggregating up to 2,50,000 equity shares (The ‘Promoter Selling Shareholder’). Other selling shareholders include private equity investor Bain Capital, as well as a certain individual selling shareholders.
The company proposes to utilise net proceeds from the fresh issue towards repayment of all or a portion of debt and general corporate purposes.
Axis Capital, BofA Securities India, Credit Suisse Securities (India), JM Financial are the Global Co-Ordinators and Book Running Lead Managers and BOB Capital Markets is the Book Running Lead Manager to the issue.
